Tekmira Halts Research On Ebola Drugs; Shifts Focus On Treating Hepatitis B

The experimental treatment for Ebola, that Tekmira Pharmaceuticals Corporation was developing, had high chances of failing in a clinical trial.

Tekmira Pharmaceuticals Corporation that has been attempting to create a potential treatment for the Ebola virus will suspend its research on Ebola drugs and soon change its name.

The experimental treatment for Ebola has high possibilities to fail in a clinical trial and hence the company aims in focusing on experimental treatments for the hepatitis B virus. The company will soon change its name to Arbutus Biopharma Corp which will be effective from August 3. Its sticker symbol will become "ABUS".

Emergent BioSolutions Awarded $20M To Develop, Manufacture Drug to Treat Ebola
The biopharmaceutical firm will develop and manufacture new Ebola monoclonal antibodies under a two year contract at its manufacturing facility at Baltimore.

The new name Arbutus Biopharma Corp will reflect its combination with OnCore BioPharma, which the Tekmira bought in March.

The company is intending to have a minimum of 4 drugs in clinical development in early 2016, as they do not have any approved drugs. Also it aims to acquire other drugs to study them in combinations.

The Ebola outbreak took more than 11000 lives, which was first reported in March 2014. The search for more effective treatment for Ebola began after experimental drugs of Tekmira was used in one patient in 2014. Other companies like NewLink Genetics Corp., Inovio Pharmaceuticals Inc., GlaxoSmithKline PLC and Allergan PLC's MAPP Pharmaceuticals unit were also involved in finding effective Ebola treatment.

Lack of Knowledge on Animal-Human Disease Transmission Puts Humanity at Risk
Research is needed on how diseases that arise in wildlife can be transmitted and evolve to become risks to human health like Ebola, SARS, MERS.

Tekmira is currently re-evaluating its development contract with the U.S. Department of Defense and will halt work on its drug TKM-Ebola. The design of the drug is based on its ability to block the genes that help the virus reproduce and spread.

Source-Medindia

Artificial-Intelligence can Predict Ebola Drugs Effectiveness 150 Times Faster
A team of researchers hunting for new Ebola treatments have come up with groundbreaking artificial-intelligence that can predict the effectiveness of new medicines 150 times faster than current methods, reveals a new research.

Experts Say Profit-Making Motive Big Hurdle for Ebola Drugs
Experts claim that money has been the biggest hurdle to erasing the curse of Ebola virus since the last 40 years.